Finding a new way to kill cancer cells in sarcoma
Triggering a New Cancer Cell Death Mechanism in Sarcoma
['FUNDING_R01'] · STANFORD UNIVERSITY · NIH-11074625
This study is exploring a new way that cancer cells can die, which could help develop better treatments for sarcoma, a type of cancer that doesn't have many good options right now, by testing a special drug in mice to see if it can trigger this process.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | STANFORD UNIVERSITY (nih funded) |
| Locations | 1 site (STANFORD, UNITED STATES) |
| Trial ID | NIH-11074625 on ClinicalTrials.gov |
What this research studies
This research investigates a novel mechanism of cell death that is different from traditional methods like apoptosis. By using small molecules, the team aims to understand how certain lipid metabolic enzymes can trigger this new form of cell death, particularly in sarcoma, a type of cancer that currently lacks effective treatments. The study will involve testing these mechanisms in genetically engineered mouse models to see if a clinical drug candidate can activate this cell death pathway. Patients may benefit from new therapeutic strategies that arise from these findings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with sarcoma who are seeking new treatment options.
Not a fit: Patients with cancers that do not respond to the mechanisms being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments for sarcoma and potentially other cancers.
How similar studies have performed: While this approach is novel, previous research has shown promise in targeting unconventional cell death mechanisms in cancer treatment.
Where this research is happening
STANFORD, UNITED STATES
- STANFORD UNIVERSITY — STANFORD, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DIXON, SCOTT — STANFORD UNIVERSITY
- Study coordinator: DIXON, SCOTT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Animal Cancer Model, Anti-Cancer Agents, anti-cancer drug, anti-cancer therapy